Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03728842 · ClinicalTrials.gov registry record
Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma
A clinical trial of Melanoma; Renal Cell Carcinoma, sponsored by Indiana University.
- Active
- Registry status
- 19
- Enrollment target
- 1
- Study location
NCT03728842: Active study of Melanoma; Renal Cell Carcinoma, sponsored by Indiana University.
NCT03728842 is a study of Melanoma; Renal Cell Carcinoma that is active but no longer recruiting, run by Indiana University. The registered enrollment target is 19 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03728842, a study of Melanoma; Renal Cell Carcinoma, is active but no longer recruiting, sponsored by Indiana University.
- ACTIVE NOT RECRUITING
- Registry status
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.
Primary Outcome
samples collected from metastatic melanoma and renal cell cancer patients
Conditions Studied
Interventions
- OTHER Blood collection for laboratory studies
- OTHER Data collection from medical record
Study Locations (1)
Indiana
- Indiana University Simon Cancer Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2004-01-04 |
| Est. Completion | 2027-03-01 |
What the registry record for NCT03728842 still lists
NCT03728842 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 1 condition, with Melanoma; Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Blood collection for laboratory studies is the first listed.
NCT03728842 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT03728842 about?
NCT03728842 is a clinical study titled "Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma". The purpose of this study is to collect blood and clinical data from patients with metastatic melanoma and renal cell cancer who have experienced spontaneous regression for studies of immune response and other factors that may influence these occurrences.
What is the current status of trial NCT03728842?
This trial is currently active not recruiting. The enrollment target is 19 participants. The study started on 2004-01-04. Estimated completion is 2027-03-01.
What conditions does trial NCT03728842 study?
This clinical trial studies the following conditions: Melanoma; Renal Cell Carcinoma.
What interventions are being tested in trial NCT03728842?
The interventions under investigation include: Blood collection for laboratory studies (OTHER), Data collection from medical record (OTHER).
Who is sponsoring clinical trial NCT03728842?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03728842 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI